EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Viral and Symptom Rebound Following Anti–Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Therapy in a Randomized Placebo-Controlled Trial

Kara W Chew iD, Brooke McGinley iD, Carlee Moser iD, Jonathan Z Li iD, Teresa H Evering, Justin Ritz, Arzhang Cyrus Javan, David Margolis, David A Wohl iD, Michael D Hughes, Eric S Daar, Judith S Currier und 3 weitere

The Journal of Infectious Diseases · 2025

DOI: 10.1093/infdis/jiae501 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Kara W Chew und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, COVID-19, COVID-19 Drug Treatment, SARS-CoV-2. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We explored viral and symptom rebound after coronavirus disease 2019 amubarvimab-romlusevimab monoclonal antibody therapy versus placebo in the randomized ACTIV-2/A5401 trial. Participants underwent nasal severe acute respiratory syndrome coronavirus 2 polymerase chain reaction testing at study days 3, 7, 14, and 28. Viral rebound was defined as RNA ≥3 and ≥0.5 log10 copies/mL increase from day 3 or 7, and symptom rebound as hospitalization or any moderate/severe symptom for ≥2 days after initial symptom improvement. There was no difference in viral rebound (∼5%/arm) (analysis population n = 713) or symptom rebound among participants who initially improved (hazard ratio, 0.95 [95% confidence interval, .52–1.75]; analysis population n = 574); <1% had both viral/symptom rebound.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCOVID-19COVID-19 Drug TreatmentSARS-CoV-2Antibodies, NeutralizingAdultAgedFemaleHumansMaleMiddle AgedDouble-Blind MethodRNA, ViralTreatment OutcomeViral Load

Stichwörter der Autor:innen

COVID-19SARS-CoV-2monoclonal antibodiesnonhospitalized adultssymptom reboundviral rebound

Substanzen

Antibodies, Monoclonal, HumanizedRNA, ViralromlusevimabamubarvimabAntibodies, Neutralizing

Autor:innen und Institutionen

  • Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
  • Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA.
  • Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
  • Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
  • Division of AIDS/National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.

ORCID-Profile: Kara W Chew, Brooke McGinley, Carlee Moser, Jonathan Z Li, David A Wohl, Joseph J Eron

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • NIH HHS
  • NCATS NIH HHS
  • National Institutes of Health

Zitieren

APA

Chew, K. W., McGinley, B., Moser, C., Li, J. Z., Evering, T. H., Ritz, J., Javan, A. C., Margolis, D., Wohl, D. A., Hughes, M. D., Daar, E. S., Currier, J. S., Eron, J. J., Smith, D. M., & Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-2/A5401 Study Team, Study Sites, and Investigators (2025). Viral and Symptom Rebound Following Anti–Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Therapy in a Randomized Placebo-Controlled Trial. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae501

Vancouver

Chew KW, McGinley B, Moser C, Li JZ, Evering TH, Ritz J, et al. Viral and Symptom Rebound Following Anti–Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Therapy in a Randomized Placebo-Controlled Trial. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiae501

BibTeX
@article{Chew2025,
  author = {Chew, Kara W and McGinley, Brooke and Moser, Carlee and Li, Jonathan Z and Evering, Teresa H and Ritz, Justin and Javan, Arzhang Cyrus and Margolis, David and Wohl, David A and Hughes, Michael D and Daar, Eric S and Currier, Judith S and Eron, Joseph J and Smith, Davey M and Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-2/A5401 Study Team, Study Sites, and Investigators, Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-2/A5401 Study Team, Study Sites, and Investigators},
  title = {Viral and Symptom Rebound Following Anti–Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Therapy in a Randomized Placebo-Controlled Trial},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  doi = {10.1093/infdis/jiae501}
}
Kostenlos starten →